ADVM Adverum Biotechnologies Inc

Price (delayed)

$1.97

Market cap

$199.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.26

Enterprise value

$156.21M

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ...

Highlights
Adverum Biotechnologies's debt has decreased by 31% YoY
ADVM's EPS is up by 20% YoY and by 5% QoQ
The quick ratio has contracted by 42% YoY but it has grown by 28% from the previous quarter
Adverum Biotechnologies's equity has shrunk by 51% YoY and by 22% QoQ

Key stats

What are the main financial stats of ADVM
Market
Shares outstanding
101.03M
Market cap
$199.02M
Enterprise value
$156.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.94
Price to sales (P/S)
55.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43.39
Earnings
Revenue
$3.6M
EBIT
-$126.11M
EBITDA
-$107.3M
Free cash flow
-$88.85M
Per share
EPS
-$1.26
Free cash flow per share
-$0.88
Book value per share
$1.02
Revenue per share
$0.04
TBVPS
$1.95
Balance sheet
Total assets
$196.77M
Total liabilities
$94.06M
Debt
$65.2M
Equity
$102.71M
Working capital
$95.74M
Liquidity
Debt to equity
0.63
Current ratio
4.32
Quick ratio
4.15
Net debt/EBITDA
0.4
Margins
EBITDA margin
-2,980.6%
Gross margin
100%
Net margin
-3,505.2%
Operating margin
-3,660.4%
Efficiency
Return on assets
-49.4%
Return on equity
-88.1%
Return on invested capital
-62.8%
Return on capital employed
-75.1%
Return on sales
-3,503.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADVM stock price

How has the Adverum Biotechnologies stock price performed over time
Intraday
-0.51%
1 week
-1.5%
1 month
65.55%
1 year
162.67%
YTD
161.69%
QTD
161.69%

Financial performance

How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$3.6M
Gross profit
$3.6M
Operating income
-$131.77M
Net income
-$126.19M
Gross margin
100%
Net margin
-3,505.2%
Adverum Biotechnologies's net income has increased by 19% YoY and by 5% QoQ
ADVM's operating income is up by 16% YoY and by 4.7% from the previous quarter
Adverum Biotechnologies's net margin has increased by 5% QoQ
Adverum Biotechnologies's operating margin has increased by 4.7% QoQ

Growth

What is Adverum Biotechnologies's growth rate over time

Valuation

What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
1.94
P/S
55.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43.39
ADVM's EPS is up by 20% YoY and by 5% QoQ
The price to book (P/B) is 116% higher than the last 4 quarters average of 0.9 and 8% higher than the 5-year quarterly average of 1.8
Adverum Biotechnologies's equity has shrunk by 51% YoY and by 22% QoQ

Efficiency

How efficient is Adverum Biotechnologies business performance
Adverum Biotechnologies's return on invested capital has shrunk by 54% YoY and by 17% QoQ
Adverum Biotechnologies's return on equity has decreased by 48% YoY and by 12% QoQ
The company's return on assets fell by 23% YoY and by 7% QoQ
ADVM's ROS is up by 5% QoQ

Dividends

What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADVM.

Financial health

How did Adverum Biotechnologies financials performed over time
The total assets is 109% greater than the total liabilities
ADVM's current ratio is down by 42% year-on-year but it is up by 31% since the previous quarter
The quick ratio has contracted by 42% YoY but it has grown by 28% from the previous quarter
Adverum Biotechnologies's debt is 37% lower than its equity
Adverum Biotechnologies's equity has shrunk by 51% YoY and by 22% QoQ
Adverum Biotechnologies's debt to equity has increased by 40% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.